7754
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammato… Read more
7754 (7754) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.771x
Based on the latest financial reports, 7754 (7754) has a cash flow conversion efficiency ratio of -0.771x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-393.16 Million) by net assets (NT$510.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
7754 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how 7754's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
7754 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 7754 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unic Technology
TWO:5452
|
0.021x |
|
EQL PHARMA AB
F:7JK
|
N/A |
|
Community Bank of the Bay
PINK:CBOBA
|
0.002x |
|
Logwin AG
XETRA:TGHN
|
0.123x |
|
Clinica Baviera
MC:CBAV
|
0.146x |
|
Stomil Sanok SA
WAR:SNK
|
0.059x |
|
LCY Technology Corp
TW:4989
|
-0.089x |
|
Resources Connection Inc
NASDAQ:RGP
|
0.082x |
Annual Cash Flow Conversion Efficiency for 7754 (2021–2024)
The table below shows the annual cash flow conversion efficiency of 7754 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$662.10 Million | NT$-186.01 Million | -0.281x | -286.74% |
| 2023-12-31 | NT$925.04 Million | NT$-67.20 Million | -0.073x | +80.43% |
| 2022-12-31 | NT$510.51 Million | NT$-189.49 Million | -0.371x | -71.89% |
| 2021-12-31 | NT$650.13 Million | NT$-140.39 Million | -0.216x | -- |